New Jersey Assembly Bill A4642

New Jersey 2026-2027 Regular Session

• Introduced: 3/10/26
• Refer: 3/10/26

Caption

Clarifies that testosterone therapy is covered treatment under the "New Jersey Menopause Coverage Act."

Impact

This legislation aims to ensure that women have access to a broader range of treatments for menopause-related health issues, addressing the needs of those who may benefit from testosterone therapy despite its potential lack of FDA approval for such use. The bill outlines that health insurance carriers are obligated to cover testosterone therapy to the same extent as other hormonal treatments without denying coverage based on FDA indications. This could potentially alleviate costs for patients and ensure they receive comprehensive care during perimenopause and menopause.

Summary

Assembly Bill A4642 proposes amendments to the New Jersey Menopause Coverage Act to clarify that testosterone therapy must be covered by health insurance providers as a treatment for women experiencing perimenopause and menopause symptoms. The bill requires that all health benefits plans delivered, issued, executed, or renewed in New Jersey must include provisions for testosterone therapy alongside other medically necessary treatments for menopause, such as hormone replacement therapy, behavioral health care services, and preventative treatments.

Contention

While proponents argue that covering testosterone therapy is vital for women's health and wellbeing during a natural but challenging phase of life, critics could raise concerns regarding the implications of allowing treatments not explicitly FDA approved for menopause. There is also a broader dialogue about the necessity and appropriateness of expanding insurance coverage for treatments traditionally viewed as elective or supplementary, which may lead to cost implications for insurance providers and potential debates around medical necessity standards in women's health.